Veeva introduces first combined pharma CRM and CLM solution for iPad

NewsGuard 100/100 Score

Today Veeva Systems unveiled Veeva iRep, the pharmaceutical industry's first complete customer relationship management (CRM) and closed loop marketing (CLM) solution built exclusively for the iPad. The new solution leverages the best of the iPad to drive efficiency through elegant CRM functionality, effectiveness via dynamic presentation of HTML5 content, and enhanced customer relationships with mobile internet connectivity. The company announced the solution to the media and customers this morning at the Four Seasons Hotel in Philadelphia along with its partners Apple, Accenture, Cognizant, HighPoint Solutions, Intouch Solutions, Mavens Consulting, and salesforce.com.

“Designed specifically to take advantage of the iPad's most remarkable aspects, iRep is a strategic solution for our customers and Veeva will invest heavily to guarantee their success.”

A significant number of global pharmaceutical and biotech companies have already started using the iPad in their sales and marketing organizations, citing its ideal size, long battery life, instant-on, and ease of use. Over the next few months, executives at five leading pharmaceutical organizations in the United States and Europe will hand out thousands of iPads installed with Veeva iRep to create competitive advantage in the market.

"The iPad arrived just in time for pharma," said Matt Wallach, chief strategy officer at Veeva Systems. "Reps are under pressure to represent more products against more competition while physicians give them less face time to do so. iRep allows them to be more efficient, more effective, and more connected. The real-time rep has truly arrived."

By combining CRM and CLM functionality on the iPad, Veeva iRep opens new possibilities for pharmaceutical companies. In addition to Veeva's market-leading CRM functionality, iRep includes a sophisticated content viewer that enables users to quickly present e-detail materials, deliver interactive presentations, and show visual data and video content on the iPad's beautiful screen. Plus, company representatives will be always connected to the internet, giving them real-time access to additional resources to further enhance customer interactions.

Veeva is partnering on the launch with Intouch Solutions, a leading interactive pharmaceutical marketing agency. As the inaugural Veeva Web Content Provider, Intouch Solutions will be providing custom creative content for iRep customers, including copy, visuals, video, and other interactive components. "We are excited to work with Veeva on the launch of iRep, which we believe will be the perfect platform for us to deliver compelling content," said Faruk Capan, CEO of Intouch Solutions. "Our customers are excited to leverage HTML5 and other dynamic technologies on a device that is nothing short of amazing."

"It is now abundantly clear that everyone loves the iPad, from pharma end users to the CFO to physicians themselves," explained Peter Gassner, CEO of Veeva Systems. "Designed specifically to take advantage of the iPad's most remarkable aspects, iRep is a strategic solution for our customers and Veeva will invest heavily to guarantee their success."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk